FDA Orphan Drug Designation for PBT2 for Huntington Disease
Filed with ASX · · 2 pages · English
Alterity Therapeutics Ltd. on 6ix
Story so far
Earlier from Alterity Therapeutics
- Prana to commence Phase 11b trial on PBT2
- Prana selects lead PD drug candidate for development
- Prana Provides Analysis of PBT2 Therapeutic Strategy for AD
- Investment by Quintiles, Placement of 225 million Shares
- Appendix 4E for the Year Ended 30 June 2010
Later from Alterity Therapeutics
- Prana announces $6.5 million R&D refund
- New Reach2HD data presented at American Neurological Assoc.
- Prana announces $4.8 million R&D refund
- Prana provides regulatory update for PBT2
- S&P DJ Indices Announces March Quarterly Rebalance
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics